EMA Authorised: Sancuso (granisetron) — Grünenthal GmbH

View source ↗

Summary

The EMA authorised Sancuso, a granisetron transdermal patch from Grünenthal GmbH, for the prevention of vomiting in cancer patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SANCUSO (GRANISETRON)

Snippet

Status: Authorised. Therapeutic area: Vomiting;Cancer. MAH: Grünenthal GmbH. Decision date: 22/11/2024